Carlyle Group portfolio
Private equity or venture capitalPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 7, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
The Q4 2024 13F filing also has internal inconsistencies and is not included in totals.
Carlyle Group reported a $10.0 bn portfolio of 19 positions to the SEC as of the end of Q2 2026. Its largest positions are MDLN, SARO, PHAT.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Carlyle Group has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
What changed this quarter
10 positions with a change (3 new, 2 added to, 1 trimmed, 4 sold).
No moves of 0.5 points of the portfolio or more.
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- MedlineMDLN73.8%
- StandardAeroSARO25.3%
- Phathom PharmaceuticalsPHAT0.4%
- Invitation HomesINVH0.2%
- Pony AIPONY0.2%
- Getty Images HoldingsGETY0.1%
- Spruce BiosciencesSPRBunder 0.1%
- SunpowerSPWRunder 0.1%
- Adicet BioACETunder 0.1%
- Forward AirFWRDunder 0.1%
- Onkure TherapeuticsOKURunder 0.1%
- Krispy KremeDNUTunder 0.1%
- Q32 BioQTTBunder 0.1%
- Riley Exploration PermianREPXunder 0.1%
- Nebius GroupNBISunder 0.1%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 75%
- ● Industrials 25%
How its portfolio changed (8 quarters)
Q2 2026: 19
Q2 2026: 100%
Q2 2026: 0.1%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Not counted as a concentrated manager: a single position is more than 70% of the portfolio; it is a private equity or venture firm; its stocks are usually holdings that went public. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Sustainable Growth AdvisersInvestment firm · $9.9 bn
- Windacre PartnershipInvestment firm · $10.1 bn
- Tortoise Capital Advisors, L.l.cInvestment firm · $9.8 bn
- Altimeter Capital ManagementInvestment firm · $9.8 bn
- Egerton Capital (UK) LLPInvestment firm · $9.8 bn
- Durable Capital PartnersInvestment firm · $10.3 bn